Celltech regroups after Pfizer fallout
Tuesday 02 December 2003
Shares in Celltech jumped yesterday on hopes the biotech company could become a takeover target after it regained the rights to market its most advanced new drug.
Pfizer, the world's largest pharmaceutical group, signalled last month that it would drop the product, a treatment for rheumatoid arthritis codenamed CDP870, unless Celltech agreed to a dramatically lower share of the profits.
Celltech said yesterday that it had refused Pfizer's demands and the partnership would be dissolved by February. The UK group will now decide whether to re-license the drug immediately or to spend an estimated $100m (£58m) conducting the last of the human trials needed.
Celltech, which is believed to have attracted takeover interest from the Swiss biotech group Serono, promised a decision on CDP870's future early in the new year.
Goran Ando, Celltech's chief executive, said he would "start returning calls" from a number of biotech and pharmaceutical companies which had expressed an interest in bankrolling CDP870 since the dispute with Pfizer became public.
Shareholders might be better served by Celltech investing in the further rheumatoid arthritis trials itself, he said. "We generate £50m of cash a year, so we can handle all the permutations," Mr Ando said. Celltech shares rose 23.5p to 375p yesterday.
- 2 Top Gear: Jodie Kidd, Philip Glenister and Guy Martin 'in advanced talks' to join show
- 3 General Election 2015: 14-year-old boy asks Nick Clegg – 'can you kill Katie Hopkins?'
- 4 University student in court for allegedly covering housemates' food in window cleaner and spit
Italian police 'reveal' what Jesus looked like as a young boy
Mysterious 'X-Files' sounds heard miles above the Earth
University student in court for allegedly covering housemates' food in window cleaner and spit
Garland shooting: Isis claims attack on Prophet Mohamed cartoon contest in Texas as its first action on US soil
Met Gala 2015: Beyoncé manages to out-skimp Rihanna, Miley and Kim Kardashian combined with near-naked ensemble
In defence of liberal democracy
The Rothschild Libel: Why has it taken 200 years for an anti-Semitic slur that emerged from the Battle of Waterloo to be dismissed?
General Election 2015: UK will be 'run for the wealthy and powerful' if Tories retain power, Labour warns
General election live: SNP suspends two members for disrupting Labour rally
Schools forced to act as 'miniature welfare states' with teachers buying underwear and even haircuts for poor pupils
Andy McSmith's Sketch: Feisty audience is the real star of an enlightening show
iJobs Money & Business
£20000 - £25000 per annum + Uncapped commission: SThree: Can you speak German,...
£25000 - £30000 per annum + benefits: Ashdown Group: An exciting opportunity f...
£215 per day: Ashdown Group: Junior Project Manager (website, web application ...
£40-50K: Guru Careers: We are seeking an experienced Software Engineer / Softw...